Cydan

NEWS
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.
Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.
AWARDS
  • NextGen Class of 2015
JOBS
IN THE PRESS